• About
    • Team
  • Technology
  • Pipeline
  • News
  • Investors
  • Careers
  • Contact

Recent Posts

  • Icosavax Appoints Thomas J. Russo Chief Financial Officer June 10, 2021
  • Icosavax Closes $100 Million Series B Financing to Advance Bivalent RSV/hMPV Vaccine Candidate Into Clinical Trials April 7, 2021
  • Lorem ipsum dolor sit met. August 29, 2016
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer porttitor imperdiet dui. Nam metus libero, iaculis et iaculis sed, suscipit vitae urna. Phasellus in tincidunt felis. August 29, 2016
  • Lorem ipsum dolor sit amet, consectetur adipiscing elit. August 29, 2016

Archives

  • June 2021
  • April 2021
  • August 2016
  • July 2016
  • June 2016
  • April 2016
  • February 2016
  • January 2016

Categories

  • Uncategorized
  • Press Releases

Archives

  • June 2021
  • April 2021
  • August 2016
  • July 2016
  • June 2016
  • April 2016
  • February 2016
  • January 2016

Icosavax Appoints Thomas J. Russo Chief Financial Officer

SEATTLE, June 10, 2021 — Icosavax, Inc. today announced the appointment of Thomas J. Russo as Chief Financial Officer. Mr. Russo

Icosavax Initiates Phase 1/2 Trial of COVID-19 VLP Vaccine Candidate

First participants dosed in a Phase 1 clinical trial to assess safety and efficacy of IVX-411 with or without Seqirus

Icosavax Closes $100 Million Series B Financing to Advance Bivalent RSV/hMPV Vaccine Candidate Into Clinical Trials

Company’s novel computationally designed virus-like particle (VLP) technology has the potential to create safe, effective, and durable vaccines against life-threatening

Icosavax Launches COVID-19 Vaccine Program with Preclinical Data and $16.5 Million in New Funding

Preclinical data published in Cell show the company’s COVID-19 vaccine candidate induces high neutralizing antibody titers after a single administration

Icosavax Launches with $51 Million Series A to Advance Computationally Designed VLP Vaccine

· Two-component virus-like particle (VLP) technology developed at the Institute for Protein Design exclusively licensed from the University of Washington

Icosavax, Inc.
1616 Eastlake Avenue E. Suite 208
Seattle, WA 98102

info@icosavax.com

Sign up for News updates

© 2022 Icosavax, Inc. All Rights Reserved.
  • Privacy policy
  • Terms of Use
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.AcceptPrivacy Policy